EVVV ev3, Inc. featured news, full reports, and detailed charts
ev3, Inc. (EVVV) Wrap Up:
ev3, Inc., a medical device company, focuses on catheter-based technologies for the endovascular treatment of vascular diseases and disorders. It develops, manufactures, and markets a range of products that include stents, atherectomy and thrombectomy products, balloon angioplasty catheters, microcatheters and occlusion balloon systems, embolic protection devices, infusion catheters/wires, embolic coils, and liquid embolics. The company markets its products in the United States, Europe, and Canada through a direct sales force, and through distributors in the United States and international markets. ev3, Inc. has a research collaboration with Merck & Co., Inc. for the analysis of atherosclero...www.ev3.net
1,250 Employees
Founded in 2000
ev3, Inc. (EVVV:NASDAQ)
LAST $12.60 USD
CHANGE TODAY -0.03 -0.24%
VOLUME 491.2K
As of 4:00 PM 11/20/09 All times are local (Market data by Reuters is delayed by at least 15 minutes).
Snapshot of ev3, Inc. (EVVV)
|
OPEN
$12.49
|
PREVIOUS CLOSE
$12.63
|
|
|
DAY HIGH
$12.64
|
DAY LOW
$12.47
|
|
|
52 WEEK HIGH
10/27/09 - $13.39
|
52 WEEK LOW
11/21/08 - $3.37
|
|
|
MARKET CAP
1.4B
|
AVERAGE VOLUME 3 mo
771.7K
|
|
|
DILUTED EPS TTM
$-2.51
|
SHARES OUTSTANDING
112.3M
|
|
|
EVVV Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
related news
M&A Activity Buoys Stocks
07/23/2007 4:39 PM ET
A fresh wave of buyouts plus earnings from Merck pushes indexes higher Monday after Friday's sell-off
EVVV Top Compensated Officers
Mr. Robert J. Palmisano
Chief Executive Officer, President and Direct...
Age: 64
Total Annual Compensation: $441.2K
Mr. Pascal E. R. Girin
Executive Vice President and President of Wor...
Age: 47
Total Annual Compensation: $479.8K
Ms. Stacy Enxing Seng
Executive Vice President and President of Per...
Age: 44
Total Annual Compensation: $326.0K
Mr. Gregory Morrison
Senior Vice President of Human Resources
Age: 46
Total Annual Compensation: $240.9K
Executives, Board Directors
Compensation as of Fiscal Year 2008.
Key developments for ev3, Inc. (EVVV)
ev3, Inc., Annual General Meeting, May 25, 2010
11/14/2009
ev3, Inc., Annual General Meeting, May 25, 2010, at 14:00 US Central Time.
ev3 Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended October 4, 2009 ; Provides Earnings Guidance for the Fourth Quarter and Full Year Ending December 31, 2009
10/27/2009
ev3 Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended October 4, 2009. For the quarter, the company reported net income of $6,736,000 or $0.06 per basic and diluted share on net sales of $112,838,000 against net loss of $7,310,000 or $0.07 per basic and diluted share on net sales of $107,029,000 for the period ended September 28, 2008. Income from operations of $7,582,000 compared to loss from operations of $4,608,000 for the period ended September 28, 2008. Income before income taxes of $7,585,000 compared to loss before income taxes of $6,794,000 for the period ended September 28, 2008. Non-GAAP adjusted net income of $19,435,000 or $0.07 per diluted share compared to adjusted net income of $3,850,000 or $0.04 per diluted share for the period ended September 28, 2008. For the nine months, the company reported net income of $28,916,000 or $0.27 per basic and diluted share on net sales of $322,319,000 against net loss of $44,502,000 or $0.43 per basic and diluted share on net sales of $316,003,000 for the period ended September 28, 2008. Income from operations of $9,262,000 compared to loss from operations of $43,628,000 for the period ended September 28, 2008. Income before income taxes of $11,405,000 compared to loss before income taxes of $42,971,000 for the period ended September 28, 2008. Non-GAAP adjusted net income of $41,118,000 or $0.38 per diluted share compared to adjusted net income of $1,924,000 or $0.02 per diluted share for the period ended September 28, 2008. The company provides earnings guidance for the fourth quarter and full year ending December 31, 2009. For the quarter, the company expects earnings per diluted share to be in the range of $0.09 to $0.13 and non-GAAP earnings per diluted share to be in the range of $0.20 to $0.24. Net sales to be in the range of $124 to $128 million. For the full year, the company expects earnings per diluted share to be in the range of $0.36 to $0.40 and non-GAAP earnings per diluted share to be in the range of $0.58 to $0.62. Net sales to be in the range of $446 to $450 million compared to $402.2 million of net product sales in 2008.
ev3, Inc. - Conference Presentation Call
09/8/2009
ev3, Inc. - Conference Presentation Calls
EVVV Competitors
| Company | Last | Change |
| AngioDynamics Inc | $15.72 USD | -0.03 |
| Integra LifeSciences Holdings Corp | $31.99 USD | +0.41 |
| Kensey Nash Corp | $23.30 USD | +0.10 |
| Micrus Endovascular Corp | $12.96 USD | -0.28 |
| Spectranetics Corp | $6.01 USD | +0.16 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | EVVV | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 3.2x |
|
| Price/Book | 1.9x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 3.1x |
|
|
EVVV |
||
|
EVVV transactions
| Type Date |
Target |
|
Merger/Acquisition
June 2, 2009 |
Chestnut Medical Technologies, Inc. |
More Recent News About ev3, Inc.
More news for EVVV
Q3 2009 ev3 Inc. Earnings Release - Before Market Open
Earnings Announcements for Tuesday, October 27CompanySymbolTimeConferenceCall3M INDIA LTD3MINDIA.BOTime Not SuppliedA.M. Castle & CoCASBefore Market OpenListenAbaxis, Inc.ABAXAfter Market CloseABILITY ENTERPRISE2374.TW03:00 am ETAcadia Realty TrustAKRAfter Market CloseListenACE LimitedACEAfter Market CloseListenActelACTL4:15 pm ETListenADVANCED TECHNOLOGY & MATERIAL000969.SZTime Not SuppliedAdvent SoftwareADVSAfter Market CloseListenAEROSPACE COMMUNICATIONS HOLDING CO600677.SSTime Not SuppliedAGCOAGCOBefore Market OpenListenAIR CHINA LTDAICAF.PKTime Not SuppliedAK Steel Holding CorpAKS08:30 am ETAKER SEAFOODS ASAAKS.OL03:30 am ETAkzo Nobel N.V.AKZOF.PK02:00 am ETAlcon Inc.ACLAfter Market CloseListen...Click here to read the whole Article (external link)
ev3 Inc. Earnings Call scheduled for 8:30 am ET today
Call Detailsev3 Inc. Earnings Conference Call (Q3 2009)Tue, Oct 27, 2009, 8:30 am EasternAbout ev3 Inc. (NasdaqGS:EVVV)ev3 Inc. operates as an endovascular company that focuses on identifying and treating peripheral vascular disease, including lower extremity arterial disease and neurovascular disease. It develops, manufactures, and markets a range of products that include stents, atherectomy plaque excision products, thrombectomy and embolic protection devices, percutaneous transluminal angioplasty balloons, and other procedural support products for the peripheral vascular market. The company also offers embolic coils, liquid embolics, flow directed, and other micro catheters; occlusion balloon systems; guidewires; and neuro stents for the neurovascular market. It markets its products in the United States, Europe, and Canada through a direct sales force; and through distributors in other international markets. The company’s customers include a section of physicians, including interventional radiologists, neuroradiologists, vascular surgeons, neuro surgeons, endovascular specialists, and interventional cardiologists. ev3 Inc. was founded in 2000 and is headquartered in Plymouth, Minnesota.More Info:Quote |Profile |Reports |Research |Msgs |Insider |Financials | Analyst Ratings...Click here to read the whole Article (external link)
ev3, Inc. Q3 2009 Earnings Call Transcript
ev3, Inc. (EVVV) Q3 2009 Earnings Call October 27, 2009 8:30 am ET Executives Julie Tracy – Senior Vice President & Chief Communications Officer Robert J. Palmisano – President, Chief Executive Officer & Director Shawn T. McCormick – Chief Financial Officer & Director Analysts David Lewis – Morgan Stanley Thomas Gunderson – Piper Jaffray Analyst for Michael Weinstein – JPMorgan Jason Mills – Canaccord Adams Joshua Zable – Natixis Bleichroeder, Inc. Larry Neibor – Baird Joanne Wuensch – BMO Capital Markets Presentation Operator Welcome to the third quarter 2009 ev3 Incorporated earnings conference call. At this time all participants are in listen only mode. Later we will conduct a question and answer session. (Operator Instructions) As a reminder, this conference is being recorded for replay purposes. I would now like to turn the conference over to your host for today, Ms. Julie Tracy. Julie Tracy Welcome to ev3’s third quarter 2009 conference call. We appreciate you joining us. I’m Julie Tracy, ev3’s Chief Communications Officer. With me on the call today are Bob Palmisano, ev3’s President and Chief Executive Officer and Shawn McCormick, ev3’s Chief Financial Officer. We issued a press release this morning regarding our third quarter 2009 results. A copy of that press release along with an investor presentation summarizing our third quarter 2009 results is available on our website at www.ev3.net. Th...Click here to read the whole Article (external link)
EV3 INC. Files SEC form 10-Q, Quarterly Report
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This Management's Discussion and Analysis provides material historical and prospective disclosures intended to enable investors and other users to assess our financial condition and results of operations. Statements that are not historical are forward-looking and involve risks and uncertainties discussed under the heading "Forward-Looking Statements" below. The following discussion of our results of operations and financial condition should be read in conjunction with our consolidated financial statements and the related notes thereto included elsewhere in this report. Business Overview We are a leading global endovascular company focused on identifying and treating peripheral vascular disease, including, in particular, lower extremity arterial disease, and neurovascular disease. Since our founding in 2000, we have been dedicated to developing innovative, breakthrough and clinically proven technologies and solutions for the treatment of peripheral vascular and neurovascular diseases, a strategy that we believe is uncommon in the medical device industry. We believe our unique approach of focusing on emerging and under-innovated opportunities, which treat peripheral vascular and neurovascular disease, allows us to compete with smaller companies that have narrow product lines and lack an international sales force and infrastructure, yet also compete with larger companies that do not have our focus and agility. We believe the overall market for endovascular devices will grow as the demand for minimally invasive treatment of vascular diseases and disorders continues to increase. We intend to capitalize on this market opportunity by the continued sales execution and introduction of new products. We expect to originate new products primarily through our internal research and development and clinical efforts, but we may supplement them with targeted acquisitions or other external ...Click here to read the whole Article (external link)
Spo Advisory Buys $9.5M Worth of Resolute Energy
Celgene Corp (CELG) Burton Graham O 39,639 $2,070,222 Berkshire Hathaway (BRK.B) Bill & Melinda Gates Foundation BO 600 $1,967,693 Carnival (CCL) Arison Micky Meir CB,CEO, BO 62,915 $1,913,913 CSX (CSX) Gooden Clarence W VP,CCO 35,000 $1,487,850 EV3 (EVVV) Emmitt Richard B DIR 100,000 $1,321,000 Boston Scientific (BSX) Abele John E DIR 100,000 $843,660 Amcol International (ACO) Washow Lawrence E DIR 25,000 $714,000 Biomed Realty Trust (BMR) Gold Alan D CB,CEO, DIR 50,000 $665,338 C H Robinson Worldwide (CHRW) Wiehoff John CEO,DIR 9,232 $516,992 Bottomline Technologies (EPAY) Eberle Robert A CEO,PR, DIR 30,000 ...Click here to read the whole Article (external link)
ev3 Inc. to Present at the 2009 Citi Investment Research Small and Mid Cap Conference on November 19, 2009
ev3 Inc. to Present at the 2009 Citi Investment Research Small and Mid Cap Conference on November 19, 2009 - Yahoo! Finance.gnwlistitemmarginbottom {margin-bottom: 10.0px} .gnwtablebottommargin {margin-bottom: 10.0px} .gnwcellpaddingleft0 {padding-left: 0.0px} .gnwverticalaligntop {vertical-align: top} .gnwtextaligncenter {text-align: center} .gnwcellparagraphmargin {margin-bottom: 0px; margin-top: 0px} .gnwverticalalignbottom {vertical-align: bottom} .gnwwhitespacenowrap {white-space: nowrap} .gnwtextalignright {text-align: right} .gnwcellpaddingright0 {padding-right: 0.0px} .gnwunderlinestyle {text-decoration: underline} .gnwtextalignleft {text-align: left} .gnw_heading {font: 16px Arial; text-align: center} .gnw_subhead {font: 12px Arial; text-align: center} .gnw_colhead {font: 12px Arial; text-align: center} .gnw_colhead_uline {font: 12px Arial; text-align: center; border-bottom: solid black 1.0pt;} .gnw_colhead_dline {font: 12px Arial; text-align: center; border-bottom: double black 2.5pt;} .gnw_label {font: 12px Arial; vertical-align: bottom; text-align: left } .gnw_label_uline {font: 12px Arial; vertical-align: bottom; text-align: left; border-bottom: solid black 1.0pt;} .gnw_label_uline_i10 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_uline_i15 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_uline_i20 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_uline_i25 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_uline_i30 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_dline {font: 12px Arial; vertical-align: bottom; text-align: left; border-bottom: double black 2.5pt;} .gnw_label_i10 {font: 12px Arial; vertical-align: bottom; text-align: left; padding-left: 10.0px;} .gnw_label_i15 {font: 12px Arial; vertical...Click here to read the whole Article (external link)
Piper Jaffray Award Winning Analyst Says Health Care Reform Equity Valuation Fears Have Passed: Stock Picks For Q4 2009
67 WALL STREET, New York - November 10, 2009 - The Wall Street Transcript has just published its Pharmaceuticals Report offering a timely review of the sector to serious investors and industry executives. This 76 page feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online. Topics covered: Small-Cap Specialty Pharma - Patent Expiration - Pending Health Care Reform - Cultivating And Expanding R&D Pipelines - Chinese Drug Manufacturers - Brisk M&A Activity - Indian Pharma VS. U.S. Pharma - Competition From Generics - FDA Approval Process - Clinical Research Outsourcing Market - Stem Cell-Based Technology - Cancer Radiation Therapy - Expansion Into Asian Markets - Traditional Chinese Medicine VS. Western Medicine In Chinese Pharma Companies include: Aeolus Pharmaceuticals (AOLS.OB); Nutra Pharma (NPHC.OB); Quick-Med Technologies (QMDT.OB); Abbott Labs (ABT); Alexza Pharmaceuticals (ALXA); AmexDrug Corporation (AXRX.OB); Aurobindo Pharma (AUROBINDOP.BO); BioClinica (BIOC); BioPharm Asia (BFAR.OB); Biocon (BIOCON.BO); Cephalon (CEPH); China Sky One Medical, Inc. (CSKI); Claris Lifesciences (CLARICH.BO); Cortex Pharmaceuticals (COR); Daiichi Sankyo (DSKYF.PK); Dr.Reddy's (RDY); Elan (Elan); Eli Lilly (LLY); Forest (FRX); GeoPharma (GORX); Glaxo (GSK); Glenmark (GLENMARK.BO); Johnson & Johnson (JNJ); Lupin (LUPINSL.BO); Mannatech (MTEX); Matrix Laboratories (ATRIXLAB.BO); Medical Nutrition (MDNU); Merck KGaA (MKGAY.PK); Mylan (MYL); N...Click here to read the whole Article (external link)
EV3 INC. Financials
Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback Quotes delayed, except where indicated otherwise.Delay times are 15 mins for NASDAQ, 20 mins for NYSE and Amex. See also delay times for other exchanges.Fundamental company data provided by Capital IQ. Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quotes are delayed at least 15 minutes. Real-...Click here to read the whole Article (external link)
Would you like to leave a comment about ev3, Inc. EVVV
Find out what social network information about ev3, Inc. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides ev3, Inc. there is more great information available at Realpennies.com